Table 1 Recent patent applications related to glycine transporters
Publication numbers | Applicants | Subject |
|---|---|---|
NZ 594930 MX 2011008633 | Abbott | Heterocyclic sulphonamide compounds that inhibit GlyT1 and are useful for treating neurological disorders, psychiatric disorders and pain |
NZ 594928 | Abbott | Aminotetraline derivatives that inhibit GlyT1 and are useful for treating disorders associated with dysfunction in glycinergic or glutamatergic neurotransmission, such as dementia, cognitive impairment and attention-deficit disorder |
WO 2011153359 KR 20130087002 | Albany Molecular Research | GlyT1 inhibitors that are useful for treating neurological or psychiatric disorders that are associated with dysfunctions in glutamatergic neurotransmission |
US 2012195985 | Amgen | Compounds that inhibit GlyT1 and are therefore useful for the treatment of cognitive disorders associated with schizophrenia, attention-deficit hyperactivity disorder and mild cognitive impairment |
US 2012094995 | AstraZeneca | 2-aza-bicyclo[2.2.1]heptane compounds that modulate GlyT1 and are useful for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, post-traumatic stress disorders and pain |
US 2013197011 TW 201321364 | Boehringer Ingelheim | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones that inhibit GlyT1 and are useful for treating the positive and negative symptoms of schizophrenia, as well as cognitive impairments associated with schizophrenia, Alzheimer's disease and other neurological and psychiatric disorders |
US 2012004273 | M.M. Ahmad et al. (GlaxoSmithKline) | GlyT1 inhibitors that are useful for treating neurological diseases such as schizophrenia, dementia or attention-deficit disorder |
MX 2013001166 | Hoffmann La Roche | A combination of a GlyT1 inhibitor and an atypical antipsychotic drug, which may be used for the treatment of the positive and negative symptoms of schizophrenia |
SI 2342197 | Hoffmann La Roche | Novel radiolabelled GlyT1 inhibitors that are useful for diagnostic imaging of GlyT1 functionality using positron emission tomography |
NZ 593279 | Hoffmann La Roche | Heteroaroylamino-substituted piperidine compounds that inhibit GlyT1 and also have good selectivity for GlyT2; useful for treating pyschoses, pain, dysfunction in memory and learning, attention-deficit disorder, schizophrenia, dementia and Alzheimer's disease |
WO 2011161006MX 2012013820 | Hoffmann La Roche | Amido-tropane derivatives that are good inhibitors of GlyT1 and have good selectivity for GlyT2; useful for treating neurological and neuropsychiatric disorders |
WO 2011161008MX 2012013580 | Hoffmann La Roche | Quinolizidine and indolizidine derivatives that are good inhibitors of GlyT1 and have good selectivity for GlyT2; useful for treating neurological and neuropsychiatric disorders |
TW 201134821MX 2012007841 | Hoffmann La Roche | Tetrahydro-pyran derivatives that are good inhibitors of GIyT1 and can be used for treating schizophrenia, psychoses and other neurological conditions including pain |
HK 1117507 IL 184353 | Hoffmann La Roche | Heterocyclic substituted phenyl methanones that inhibit GlyT1 and can be used for treating schizophrenia |
IL 184439 | Hoffmann La Roche | 2,5-disubstituted phenyl methanone derivatives that are GlyT1 inhibitors and are useful for treating CNS disorders such as schizophrenia, cognitive impairment and Alzheimer's disease |
EP 2617715 CA 2827372 TW 201236682 | Taisho Pharma Company | GlyT inhibitors that inhibit glycine uptake and are useful for treating schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders, depression, drug addiction, spasms, tremors, pain and sleep disorders |
TW 201225956 TW 201225955 | Taisho Pharma Company | A GlyT inhibitory substance that is useful for treating schizophrenia, Alzheimer's disease, cognitive dysfunction, anxiety disorders, depression, drug dependence, convulsions, pain and sleep disorders |
US 2012010414 US 2012116095 | Taisho Pharma Company | GlyT inhibitors that are useful for the treatment of schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders and depression, and can be used in combination with antipsychotics and antidepressants |
